The results from the study were published in the Journal of Clinical Oncology. The shares closed at $7.32 on Friday. Dendreon stock surged in early April, reaching an all-time high of $25.25 after a Food and Drug Administration panel …
CNBC10y
An analyst apologized to clients late Wednesday for his calls on troubled biotechnology company Dendreon Corp., as he moved his rating on the shares to hold from buy in the wake of the company lowering sales estimates for the coming …
Valeant’s stock lost 12% against the industry’s gain of 5.5% ... During the quarter, the company completed sale of Dendreon Pharmaceuticals LLC and used net …
Shares of Dendreon surged to their highest point in two years Tuesday after the biotechnology company said its prostate-cancer drug Provenge extended survival, improving its odds of FDA approval. NEW YORK–Shares of Dendreon surged …
Valeant recently used $811 million of its proceeds from its Dendreon divestiture …
However, the analyst retained his Hold rating on the stock, arguing that the stock is in danger of becoming “a perpetual restructuring megacap tech story.” Dendreon Corp. (NASDAQ: DNDN) slumped more than 66% on Thursday, a day …
You brought some new stock picks, beginning with a biotech firm, DNDN the ticker symbol and Dendreon. What do you like about this one? KRAMER: Dendreon to me is a blockbuster. It's revolutionary new way to treat cancer. On May 1 …
After the directors sold much of their Dendreon stock at the top of the market, Dendreon later announced that its earnings projections were not achieved because of doctors' reluctance to use its treatment when reimbursement for its …
DNDN is poised to plunge 69.2% -- deeper into penny-stock territory -- after the firm filed for Chapter 11 bankruptcy protection. Dendreon Corporation said it's reached deals with some bond holders regarding a financial restructuring -- …
Valeant stock surged as much as 6% Tuesday on the news. Take Dendreon, which makes cancer immunotherapy treatment Provenge, for example. In February 2015, Valeant paid $495 million for Dendreon, which was then in …